TINAG, EPHB2, and FCN3 were identified as critical signaling molecules and potential targets for the treatment of CRC, which deserve further exploration to confirm their efficacy and mechanisms more comprehensively, and in particular, to evaluate their effectiveness and safety as targeted therapy strategies in clinical trials. Here, FCN3 is linked to colorectal carcinoma.